Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 201–300 of 1,001
Increased low-frequency brain responses to music after psilocybin therapy for depression
Wall, M. B., Lam, C., Ertl, N., Kaelen, M., Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.081 · Cited by 49
Self-citationPsilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
“17) but noted significantly higher positive response for the psilocybin-assisted therapy group in QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ⩽5) at week 6 (Carhart-Harris et al., 2021).”
BackgroundInfluentialMolecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
“In fact, 5 - HT2A receptor agonists have been shown to produce antidepressant effects in both rodents ( 71 – 74 ) and humans ( 75 , 76 , 77 ), and recent evidence suggests that LSD may have procognitive effects ( 78 ).”
The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
Page, L., Rehman, A., Syed, H., Forcer, K., & Campbell, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.743599 · Cited by 44
“depressive disorders (7, 8), cancer-related anxiety (9) and alcohol dependence (10).”
BackgroundGolden, C. T., & Chadderton, P. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-16325-w · Cited by 49
Qu, Y., Chang, L., Ma, L., Wan, X., & Hashimoto, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173500 · Cited by 48
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 40
“…one recent trial involving an active comparator and ‘ double-dummy ’ and double-blind procedures, psilocybin therapy (PT) showed efficacy superior to escitalopram treatment (ET) across most depression outcomes measured – but not the primary outcome (Barba et al., 2022; Carhart-Harris et al., 2021).”
InfluentialSelf-citationVilliger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 45
The Economics of Treatment for Depression
Stecher, C. D., Cloonan, S., & Domino, M. E. (2023) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-061022-040533 · Cited by 51
Genetic Survey of Psilocybe Natural Products
Dörner, S., Rogge, K., Fricke, J., Schäfer, T., Wurlitzer, J. M., Gressler, M., Pham, D. N. K., Manke, D. R., Chadeayne, A. R., & Hoffmeister, D. (2022) · ChemBioChem · doi:10.1002/cbic.202200249 · Cited by 39
McCrone, P., Fisher, H., Knight, C., Harding, R., Schlag, A. K., Nutt, D. J., & Neill, J. C. (2023) · Psychological Medicine · doi:10.1017/s0033291723001411 · Cited by 42
Self-citationKoslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 45
“One trial controlled with waiting list [30], and one study used a double-dummy RCT to compare psilocybin to 6 weeks of an SSRI [34].”
BackgroundKnowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Glynos, N. G., Pierce, J. M., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022817 · Cited by 46
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
Bedford, P., Hauke, D. J., Wang, Z., Röth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01574-8 · Cited by 46
“, escitalopram), while being associated with far fewer side effects (Carhart-Harris et al., 2021).”
BackgroundMertens, L. J., Koslowski, M., Betzler, F., Evens, R., Gilles, M., Jungaberle, A., Jungaberle, H., Majić, T., Ströhle, A., Wolff, M., et al. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100104 · Cited by 41
Orłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Inserra, A., Giorgini, G., Lacroix, S., Bertazzo, A., Choo, J. M., Markopolous, A., Grant, E., Abolghasemi, A., Gregorio, D. D., Flamand, N., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15977 · Cited by 44
“…a fundamental role in neurophysiology, behaviour and mental health via the gut–brain axis and its therapeutic manipulation represents both a novel frontier and a research priority in psychiatry (Chinna Meyyappan et al., 2020; Inserra et al., 2018; Settanni et al., 2021; Shoubridge et al., 2022).”
BackgroundWeiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 50
“In the original trial, PT demonstrated comparable treatment efficacy on the primary outcome measure in comparison with ET, but superior efficacy (by > 95% confidence on each) on 14 of 16 efficacy outcome measures overall (Carhart-Harris et al., 2021a, 2021b).”
Self-citationPsychedelics for Brain Injury: A Mini-Review
Khan, M., Carter, G. T., Aggarwal, S. K., & Holland, J. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.685085 · Cited by 43
“The subjective hallucinogenic effects of psychedelics, with clinical psychological support, may also prove valuable in fostering recovery from brain injury from a trauma recovery rehabilitation psychology standpoint due to their anti-PTSD and anti-depression effects that are now well-documented (81, 82).”
BackgroundMoral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
Langlitz, N., Dyck, E., Scheidegger, M., & Repantis, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680064 · Cited by 44
“comparing psilocybin and escitalopram in long-standing, moderate-to-severe major depressive disorder did not show significant difference in antidepressant effects, it produced secondary effects on qualitative dimensions of psychosocial functioning that transformed patients’ attitudes toward themselves, others, and the…”
BackgroundJones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066714 · Cited by 43
“These findings also add to the growing evidence that psilocybin is associated with decreased risk of depression and may be useful for treating depressive symptoms (Carhart-Harris et al., 2021; Davis et al., 2021; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundPsilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
Alper, K., Cange, J., Sah, R., Schreiber-Gregory, D., Sershen, H. W., & Vinod, K. Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1074633 · Cited by 46
“, 2017), and mood and anxiety disorders (Ross et al., 2016; Carhart-Harris et al., 2021).”
BackgroundNeuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
“Modularity was assessed in two groups; patients from the initial open-label study [42] and patients from a double-blind study where psilocybin was compared with the selective serotonin reuptake inhibitor (SSRI) escitalopram [44].”
MethodSelf-citationPsilocybin in Treatment-Resistant Depression
Madras, B. K. (2022) · New England Journal of Medicine · doi:10.1056/nejme2210975 · Cited by 45
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Kelly, J. R., Clarke, G. A., Harkin, A., Corr, S. C., Galvin, S. D., Pradeep, V., Cryan, J. F., O’Keane, V., & Dinan, T. G. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100349 · Cited by 45
Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
Mallaroni, P., Mason, N. L., Reckweg, J. T., Paci, R., Ritscher, S., Toennes, S. W., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2958 · Cited by 46
Sakurai, H., Yonezawa, K., Tani, H., Mimura, M., Bauer, M., & Uchida, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1714-9097 · Cited by 42
Yu, C., Liang, C., Yang, F., Tu, Y., Hsu, C., Carvalho, A. F., Stubbs, B., Thompson, T., Tsai, C., Yeh, T., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040938 · Cited by 43
“For example, a recent RCT used a very low dose of psilocybin (1 mg) as an “active” placebo [34].”
BackgroundMethodInfluentialOlsen, A. S., Lykkebo-Valløe, A., Ozenne, B., Madsen, M. K., Stenbæk, D. S., Armand, S., Mørup, M., Ganz, M., Knudsen, G. M., & Fisher, P. M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119716 · Cited by 42
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 47
“13,27 Third, we suggest using two different study designs to reduce expectancy effects.”
InfluentialPsilocybin and Other Classic Psychedelics in Depression
Nutt, D. J., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 43
Self-citationRichardson, E., Patterson, R., Meltzer-Brody, S. E., McClure, R. W., & Tow, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050423-095712 · Cited by 52
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“The first randomized trial comparing psilocybin with escitalopram demonstrates secondary outcomes generally favored psilocybin, although with no significant difference in antidepressant effects [81].”
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., & Sergent, F. (2025) · Addiction · doi:10.1111/add.70152 · Cited by 43
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
“Ketamine and psilocybin can both produce rapid improvements in psychiatric conditions like depression that persist for days or weeks beyond the excretion of the drugs and their metabolites (25, 91).”
BackgroundMethodInfluentialA Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2025.116359 · Cited by 39
Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0132 · Cited by 43
Coppola, M., Bevione, F., & Mondola, R. (2022) · Journal of Xenobiotics · doi:10.3390/jox12010004 · Cited by 41
“Statistical analysis showed a significant decrease in GRID-HAMD scores from baseline to weeks 1 and 4 [86].”
MethodPsychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 41
“For psilocybin, a recent phase-2-study with 59 patients with moderate to severe unipolar depression showed a similar—but not greater—efficacy of the substance compared to the SSRI escitalopram over a duration of 6 weeks (Carhart-Harris et al., 2021).”
ResultToward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 40
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 40
“[121].”
BackgroundExploring mechanisms of psychedelic action using neuroimaging
Erritzøe, D., Timmermann, C., Godfrey, K., Castro-Rodrigues, P., Peill, J. M., Carhart-Harris, R. L., Nutt, D. J., & Wall, M. B. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00172-3 · Cited by 42
“69).”
Self-citationNew Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
Noorani, T. N., & Martell, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727050 · Cited by 38
“escitalopram for depression reported differences in the primary outcome measure (the QIDS-SR16) between experimental and control arms as statistically insignificant (1).”
BackgroundSelf-citationThe Potential of Psychedelics for End of Life and Palliative Care
Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_278 · Cited by 39
Pottie, E., & Stove, C. P. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15570 · Cited by 37
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
Johnson, M. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_327 · Cited by 49
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
Kozell, L. B., Eshleman, A. J., Swanson, T. L., Bloom, S. H., Wolfrum, K. M., Schmachtenberg, J. L., Olson, R. J., Janowsky, A. J., & Abbas, A. I. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001454 · Cited by 37
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 38
Psychedelic use and psychiatric risks
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06478-5 · Cited by 41
“depressive symptoms (Carhart-Harris et al. 2021; see also, Goodwin et al. 2022; von Rotz et al. 2023).”
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 40
Self-citationErritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D. J., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 43
“These results provide a more nuanced interpretation of the results presented in (Carhart-Harris et al., 2021), which reported an absence of evidence for an effect of treatment condition in the primary outcome QIDS-SR-16 (despite there being between-subjects differences in other measures of…”
BackgroundMethodResultInfluentialSelf-citationBreathwork-induced psychedelic experiences modulate neural dynamics
Lewis-Healey, E., Tagliazucchi, E., Canales‐Johnson, A., & Bekinschtein, T. A. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae347 · Cited by 43
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058933 · Cited by 38
“…et al., 2006); additionally, recent trials indicate that psychedelic compounds like psilocybin (the active compound in “magic mushrooms”) may alleviate a host of mental health conditions, including depression (Carhart-Harris et al., 2021; Davis et al., 2021) and anxiety (Grob et al., 2011).”
BackgroundThe Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns
Johnston, C. B., Mangini, M., Grob, C. S., & Anderson, B. T. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.08.007 · Cited by 40
“A phase II double-blind randomized trial of two doses of psilocybin vs daily escitalopram (both with psychosocial support) in major depression (N=59, mean age 41 years) also resulted in clinically meaningful pre-post changes in depression symptoms, but did not ultimately demonstrate superiority on the primary endpoint…”
ResultSøndergaard, A., Madsen, M. K., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.948729 · Cited by 38
Takaba, R., Ibi, D., Yoshida, K., Hosomi, E., Kawase, R., Kitagawa, H., Goto, H., Achiwa, M., Mizutani, K., Maeda, K., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02778-x · Cited by 39
“These findings are supported by various clinical studies (Carhart-Harris et al. 2021; Davis et al. 2021; Goodwin et al. 2022; Gukasyan et al. 2022).”
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Meling, D., Ehrenkranz, R. C., Nayak, S. M., Aicher, H., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024) · Psychoactives · doi:10.3390/psychoactives3020014 · Cited by 35
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J. K. E., Bessa, B. S., d’Orsi, D., Schoevers, R. A., & Oliveira-Maia, A. J. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00333-x · Cited by 39
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 39
“For comparison, we examined 5D-ASC scores from a previous trial of psilocybin therapy for MDD [64] that also administered a 25 mg dose.”
Stupak, R., & Dobroczyński, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126625 · Cited by 39
“As one of the authors of a recent trial [82] comparing psilocybin and escitalopram commented: “if psilocybin becomes just another drug, it will be as uninspiring and ultimately disappointing as SSRIs have been for many” [83].”
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 41
Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s096318012200007x · Cited by 42
“10 In the past two decades, clinical trials on psilocybin have demonstrated a significant potential to increase well-being, 11,12,13 as well as decrease anxiety, 14,15 decrease depression, 16,17,18 and treat substance use disorders such as alcohol use disorder and tobacco use disorder.”
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 42
Hernández-León, A., Escamilla-Orozco, R. I., Tabal-Robles, A. R., Martínez-Vargas, D., Romero-Bautista, L., Escamilla-Soto, G., Romero, O. S. G., Torres-Valencia, J. M., & González-Trujano, M. E. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117415 · Cited by 35
Liu, J., Tian, Y., Yang, S., Zhong, X., He, W., Xu, M., Fang, J., Deng, M., Xu, N., Zeng, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967670 · Cited by 36
“At present, synthesized drugs are the most commonly used and effective treatmentmeans in clinical traits, which have disadvantages such as low effective rate, serious side effects, and high price (Krishnan and Nestler, 2008; Carhart-Harris et al., 2021).”
BackgroundSiva, J. B., Barba, T., Kettner, H., Kuc, J., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231224217 · Cited by 39
“While it is common practice to stop taking SRIs at least 2 weeks before the psychedelic experience in recent clinical trials (Carhart-Harris et al., 2016, 2021; Davis et al., 2021; Malcolm & Thomas, 2022), we previously found that discontinuing SRIs before trial start negatively impacted the…”
BackgroundSelf-citationFang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 35
“The therapeutic effects of psilocybin in treating depression can be observed within a day, surpassing the rapidity of nearly all current fi rst-line antidepressants (18, 20, 21, 24, 51, 57), while its ef fi cacy is comparable and not inferior (7, 58, 59).”
BackgroundResultInfluentialEllis, S., Bostian, C. M., Feng, W., Fischer, E. G., Schwartz, G., Eisen, K., Lean, M., Conlan, E., Ostacher, M. J., Aaronson, S. T., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.133 · Cited by 38
Pearson, C. S., Siegel, J. S., & Gold, J. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120096 · Cited by 36
Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221081380 · Cited by 39
Psychedelics alter metaphysical beliefsPreprint
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f6sjk · Cited by 35
Self-citationGarel, N., Lévesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., Richard‐Devantoy, S., & Greenway, K. T. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1200393 · Cited by 35
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 37
Aarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“Clinical research to date has found benefits related largely to higher dose administration of classic psychedelics (Anderson et al. 2020; Bogenschutz et al. 2015; Carhart-Harris et al. 2021; Davis et al. 2021; Griffiths et al. 2016; Johnson et al. 2014).”
Molecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 36
Rossi, G. N., Guerra, L. T. L., Baker, G. B., Dursun, S. M., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Biomolecules · doi:10.3390/biom12111618 · Cited by 40
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 54
“, 2021), psilocybin (Carhart-Harris et al., 2021; Gukasyan et al., 2022), and ayahuasca for depression (Palhano-Fontes et al.”
BackgroundAre psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
Zia, F. Z., Baumann, M. H., Belouin, S. J., Dworkin, R. H., Ghauri, M. H., Hendricks, P. S., Henningfield, J. E., Lanier, R. K., Ross, S., & Berger, A. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109528 · Cited by 34
Techniques for in vivo serotonin detection in the brain: State of the art
Zhao, S., & Piatkevich, K. D. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15865 · Cited by 38
Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D. (2024) · Psychological Review · doi:10.1037/rev0000455 · Cited by 38
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
“Most of the current results stem from phase 1 studies, with only two phase 2 studies being published so far [13, 17].”
BackgroundWhitfield, H. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727572 · Cited by 33
“An ACT-informed psychedelic study protocol also leant towards “supportive” and “non-directive” guide-therapists with emotional direction coming mainly from a musical playlist during the medication phase [(15), p.”
BackgroundBahji, A., Lunsky, I. O., Gutiérrez, G., & Vázquez, G. H. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2278586 · Cited by 34
“Murphy et al. (2022) reported follow-up data on the study by Carhart-Harris et al. (2021), finding that a stronger therapeutic alliance and rapport between the therapist and the patient were associated with greater reductions in depressive symptoms and improved well-being following the therapy.”
Thal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 38
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 34
Avram, M., Fortea, L., Wollner, L., Coenen, R., Korda, A. I., Rogg, H. V., Holze, F., Vizeli, P., Ley, L., Raduà, J., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02734-y · Cited by 35
“…substances like lysergic acid diethylamide (LSD), psilocybin, and N, N-dimethyltryptamine (DMT), has garnered signi fi cant attention due to the potential they have shown to reduce symptoms associated with various psychiatric disorders, such as depression, anxiety, and addiction [1 – 4].”
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis
Hieronymus, F., López, E., Sjögren, H. W., & Lundberg, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.24119 · Cited by 34
Roscoe, J., & Lozy, O. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085222 · Cited by 34
“…were reported to be transient and mild, the most common being headaches (Bogenschutz et al., 2015; Brown et al., 2017; Carhart-Harris et al., 2016; Carhart-Harris et al., 2021; Davis et al., 2021; Griffiths et al., 2016; Johnson et al., 2014; Preller et al., 2020; Ross et al., 2016; Schindler et…”
BackgroundInfluentialMDMA for the Treatment of Negative Symptoms in Schizophrenia
Arnovitz, M. D., Spitzberg, A. J., Davani, A. J., Vadhan, N. P., Holland, J. A., Kane, J. M., & Michaels, T. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123255 · Cited by 33
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 35
“These are often, after all, the people present during one of the most meaningful experiences of a participant’s life [25].”
BackgroundSelf-citationMortaheb, S., Fort, L. D., Mason, N. L., Mallaroni, P., Ramaekers, J. G., & Demertzi, A. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.04.001 · Cited by 41
Teacher plants — Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives
Berlowitz, I., O’Shaughnessy, D. M., Heinrich, M., Wolf, U., Maake, C., & Martin-Söelch, C. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114910 · Cited by 32
Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy
Mocanu, V., Mackay, L., Christie, D., & Argento, E. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00468-0 · Cited by 34
“Abbreviations PAP: Psychedelic-assisted psychotherapy; SAP: Special Access Program; LSD: Lysergic acid diethylamide; MDMA: 3,4-methylenedioxymethamphetamine; RCT : Randomized control trial; PTSD: Post-traumatic stress disorder; CDSA: Controlled Drugs and Substances Act; US: United States; FDA: Food and Drug Administra…”
BackgroundInfluentialPsychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 37
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.